Blood Research最新文献_第4页

Treatment outcome and prognostic factors in relapsed pediatric acute myeloid leukemia. 复发儿童急性髓系白血病的治疗结果和预后因素。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-06 DOI: 10.5045/br.2023.2023152

Jung Hwan Lee, Hee Young Ju, Ju Kyung Hyun, So Jin Kim, Hee Won Cho, Jae Kyung Lee, Ji Won Lee, Ki Woong Sung, Keon Hee Yoo

{"title":"Treatment outcome and prognostic factors in relapsed pediatric acute myeloid leukemia.","authors":"Jung Hwan Lee, Hee Young Ju, Ju Kyung Hyun, So Jin Kim, Hee Won Cho, Jae Kyung Lee, Ji Won Lee, Ki Woong Sung, Keon Hee Yoo","doi":"10.5045/br.2023.2023152","DOIUrl":"10.5045/br.2023.2023152","url":null,"abstract":"Background: Despite improved outcomes for pediatric patients with acute myeloid leukemia (AML), the prognosis for relapse remains poor. This study aimed to examine the clinical factors associated with prognosis in relapsed pediatric AML.Methods: We conducted a chart review of pediatric patients with AML who experienced their first relapse and received treatment at our institution between 2008 and 2019. Risk stratification at diagnosis was performed according to the definition suggested by the ongoing AML 2012 study in Korea, and the clinical factors associated with prognosis were analyzed.Results: A total of 27 pediatric patients with relapsed AML were identified. The 5-year overall survival (OS) and event-free survival (EFS) rates were 32.9% and 32.9%, respectively. A duration ≥12 months from diagnosis to relapse had a favorable impact on survival outcomes (5-yr OS, 64.0% vs. 15.7%; P=0.007). Patients who achieved complete remission (CR) after 1 course of chemotherapy following relapse (N=15) had a 5-year OS rate of 59.3%, while none of the other patients survived (P＜0.0001). Additionally, the 5-year OS differed significantly based on the risk group at initial diagnosis (62.3% [favorable and intermediate prognosis groups, N=11] vs. 13.3% [poor prognosis group, N=15]; P=0.014).Conclusion: Patients with a longer duration of CR before relapse, who achieved CR following 1 course of reinduction chemotherapy, and were in the favorable or intermediate prognosis group at diagnosis demonstrated better outcomes. These findings emphasize the importance of tailoring treatment strategies based on the expected prognosis at relapse in pediatric patients with AML.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71487239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incidental abdominal computed tomography findings in patients newly diagnosed with Philadelphia-negative myeloproliferative neoplasm. 新诊断为费城阴性骨髓增生性肿瘤的患者的偶然腹部计算机断层扫描结果。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-10-19 DOI: 10.5045/br.2023.2023049

Ik-Chan Song, Jeong Suk Koh, Sora Kang, Myung-Won Lee, Kyung Sook Shin, Deog-Yeon Jo

引用次数: 0

TP53 mutation is a high-risk factor for Richter's syndrome based on circulating tumor DNA. 根据循环肿瘤DNA，TP53突变是里希特综合征的高危因素。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-06 DOI: 10.5045/br.2023.2023189

Hee Sue Park, Bo Ra Son, Seung Myoung Son, Jihyun Kwon

引用次数: 0

Clinically relevant core genes for hematologic malignancies in clinical NGS panel testing. 临床NGS小组测试中血液系统恶性肿瘤的临床相关核心基因。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-06 DOI: 10.5045/br.2023.2023196

Ju Sun Song

引用次数: 0

Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement. 来那度胺是治疗 AL 淀粉样变性和心脏受累患者的一种方法。

IF 2.2

Blood Research Pub Date : 2023-12-31 DOI: 10.5045/br.2023.2023194

Seo Yoon Jang, Ja Min Byun, Sung-Soo Yoon, Jin Chul Paeng, Seung-Pyo Lee, Youngil Koh

引用次数: 0

A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma. 伊布替尼治疗复发或难治套细胞淋巴瘤疗效的回顾性分析。

IF 2.2

Blood Research Pub Date : 2023-12-31 DOI: 10.5045/br.2023.2023208

Yong-Pyo Lee, Ye Ji Jung, Junhun Cho, Young Hyeh Ko, Won Seog Kim, Seok Jin Kim, Sang Eun Yoon

{"title":"A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma.","authors":"Yong-Pyo Lee, Ye Ji Jung, Junhun Cho, Young Hyeh Ko, Won Seog Kim, Seok Jin Kim, Sang Eun Yoon","doi":"10.5045/br.2023.2023208","DOIUrl":"10.5045/br.2023.2023208","url":null,"abstract":"Background: While treatment strategies for mantle cell lymphoma (MCL) have evolved, patients often experience disease progression and require additional treatment therapies. Ibrutinib presents a promising option for relapsed or refractory MCL (RR-MCL). This study investigated real-world treatment outcomes of ibrutinib in patients with RR-MCL.Methods: A single-center retrospective analysis investigated clinical characteristics and survival outcomes of patients with RR-MCL, treated with ibrutinib.Results: Forty-two patients were included, with 16 received rituximab and bendamustine, and 26 receiving anthracycline-based regimens as front-line treatment. During a median follow-up of 46.0 months, the response rate to ibrutinib was 69%, with 12 CRs and 8 partial responses. Disease progression (54.8%) and adverse events (11.9%) were the primary reasons for discontinuation. Median progression-free survival (PFS) and overall survival (OS) were approximately 16.4 and 50.1 months, respectively. Patients older than 70 years (P=0.044 and P=0.006), those with splenomegaly (P=0.022 and P=0.006), and those with a high-risk simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI) (P＜0.001 and P＜0.001) exhibited siginificantly inferior PFS and OS. Notably, patients with a high-risk sMIPI relapsed earlier. Post-ibrutinib treatment yilded an OS of 12.2 months, while clinical trial participants demonstrated superior survival compared to those receiving chemotherapy alone.Conclusion: This study underscores the importance of considering patient characteristics before administering ibrutinib as salvage therapy. Early relapse was associated with poor outcomes, highlighting the need for novel therapeutic strategies.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study. brentuximab vedotin在复发或难治性cd30阳性淋巴瘤患者中的多中心非介入性注册:CISL1803/BRAVO研究

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023206

Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang

{"title":"A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.","authors":"Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang","doi":"10.5045/br.2023.2023206","DOIUrl":"10.5045/br.2023.2023206","url":null,"abstract":"Background: Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, including mycosis fungoides (MF). However, there are limited data reflecting real-world experiences with BV treatment for HL, ALCL, and MF.Methods: This was a multicenter, non-interventional registry study of the efficacy and safety of BV in patients with relapsed or refractory CD30-positive lymphoma (CISL1803/BRAVO). Outcomes were determined based on the occurrence of relapse or progression and overall survival after BV treatment.Results: A total of 85 patients were enrolled in this study. The median number of BV cycles was 10 (range, 2‒16) in the patients with HL. The objective response rate (ORR) of patients with HL to BV was 85.4% (41/48), comprising 27 complete responses (CRs) and 14 partial responses (PRs). The ORR of ALCL was 88% (22/25), consisting of 17 CRs and five PRs, whereas the ORR of MF was 92% (11/12). At the median follow-up of 44.6 months after BV treatment, the median post-BV progression-free survival of HL, ALCL, and MF patients was 23.6 months, 29.0 months, and 16.7 months, respectively (P=0.641). The most common side effect of BV was peripheral neuropathy; 22 patients (25.9%, 22/85) experienced peripheral neuropathy (all grades).Conclusion: The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

T-cell large granular lymphocytic leukemia with low-grade bone marrow involvement complicated by acquired pure red cell aplasia. t细胞大颗粒淋巴细胞白血病伴低级别骨髓受累并获得性纯红细胞发育不全。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-15 DOI: 10.5045/br.2023.2023141

Bernhard Strasser, Sonja Heibl, Josef Thaler, Alexander Haushofer

引用次数: 0

Clinico-pathological features and treatment outcomes of high-grade B cell lymphoma-a tertiary cancer center experience. 高级别B细胞淋巴瘤的临床病理特征和治疗结果-三级癌症中心的经验。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023169

Anindya Mukherjee, Sujay Rainchwar, Aakanksha Singh, Rohan Halder, Pritish Chandra Patra, Rayaz Ahmed, Dinesh Bhurani, Narendra Agrawal

引用次数: 0

Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation. 自体干细胞移植后移植物功能差的多发性骨髓瘤患者应用罗米普罗stim成功恢复移植物功能差。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023185

Jeongmin Yim, Sung-Soo Park, Jong-Mi Lee, Jae-Ho Yoon, Hee-Je Kim, Chang-Ki Min

引用次数: 0